

HCV Directly Acting Antivirals & RBV

Charts revised March 2017. Full information available at www.hep-druginteractions.org

Page 1 of 5

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BOC, Boceprevir; DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; TVR, Telaprevir; VEL, Velpatasvir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

Table 1: Matrix showing drug interactions for HCV DAAs and RBV across categories: Anaesthetics & Muscle Relaxants, Analgesics, Anthelmintics, Antiarrhythmics, Antibacterials, and Anticoagulant/Antiplatelet & Fibrinolytic. Columns include BOC, DCV, EBR/GZR, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, TVR, VEL/SOF, RBV.

Table 2: Matrix showing drug interactions for HCV DAAs and RBV across categories: Antibacterials (continued), Anticoagulant, Antiplatelet & Fibrinolytic, and Anticonvulsants. Columns include BOC, DCV, EBR/GZR, LED/SOF, OBV/PTV/r, OBV/PTV/r+DSV, SMV, SOF, TVR, VEL/SOF, RBV.

For personal use only. Not for distribution.

Key to symbols: Legend for interaction symbols: red dot (no coadministration), orange square (additional monitoring), yellow triangle (weak intensity), green diamond (no significant interaction).

- Notes: Further information available at www.hep-druginteractions.org; Predicted interactions based on known metabolic pathways; Caution required in patients with hepatic impairment; Where advice differs between countries, charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BOC, Boceprevir; DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; TVR, Telaprevir; VEL, Velpatasvir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

Table listing drug interactions for various categories including Antivirals, Anxiolytics/Hypnotics/Sedatives, Beta Blockers, Bisphosphonates, Bronchodilators, Calcium Channel Blockers, and Contraceptives and Hormonal Replacements. Columns represent different HCV DAAs and RBV.

Table listing drug interactions for various categories including Cytotoxics, Erectile Dysfunction Agents, and Gastrointestinal Agents. Columns represent different HCV DAAs and RBV.

For personal use only. Not for distribution.

Key to symbols

Table defining symbols: red dot for no coadministration, orange square for significant interaction, yellow triangle for weak intensity, and green diamond for no significant interaction.

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways.
Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies...

© Liverpool Drug Interactions Group, University of Liverpool
Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF
We aim to ensure that information is accurate and consistent with current knowledge and practice...

HCV Directly Acting Antivirals & RBV

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BOC, Boceprevir; DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; TVR, Telaprevir; VEL, Velpatasvir; RBV, Ribavirin. Cells have been left blank for the unassessed interactions with RBV.

	BOC	DCV	EBR/ GZR	LED/ SOF	OBV/ PTV/r +DSV	OBV/ PTV/r +DSV	SMV	SOF	TVR	VEL/ SOF	RBV
Lipid Lowering Agents											
Atorvastatin	■	■	■	■	■	■	■	■	■	■	■
Bezafibrate	■	■	■	■	■	■	■	■	■	■	■
Ezetimibe	■	■	■	■	■	■	■	■	■	■	■
Fenofibrate	■	■	■	■	■	■	■	■	■	■	■
Fish oils	■	■	■	■	■	■	■	■	■	■	■
Fluvastatin	■	■	■	■	■	■	■	■	■	■	■
Gemfibrozil	■	■	■	■	■	■	■	■	■	■	■
Lovastatin	■	■	■	■	■	■	■	■	■	■	■
Pitavastatin	■	■	■	■	■	■	■	■	■	■	■
Pravastatin	■	■	■	■	■	■	■	■	■	■	■
Rosuvastatin	■	■	■	■	■	■	■	■	■	■	■
Simvastatin	■	■	■	■	■	■	■	■	■	■	■
Oxytocics											
Ergometrine (ergonovine)	■	■	■	■	■	■	■	■	■	■	■
Mifepristone	■	▲	■	■	■	■	■	■	■	■	■
Misoprostol	■	■	■	■	■	■	■	■	■	■	■
Parkinsonism Agents											
Benzotropine	■	■	■	■	■	■	■	■	■	■	■
Carbidopa	■	■	■	■	■	■	■	■	■	■	■
Orphenadrine	■	■	■	■	■	■	■	■	■	■	■
Pramipexole	■	■	■	■	■	■	■	■	■	■	■
Rasagiline	■	■	■	■	■	■	■	■	■	■	■
Ropinirole	■	■	■	■	■	■	■	■	■	■	■
Steroids											
Beclometasone	■	■	■	■	■	■	■	■	■	■	■
Betamethasone	■	■	■	■	■	■	■	■	■	■	■
Budesonide	■	■	■	■	■	■	■	■	■	■	■
Ciclesonide	■	■	■	■	■	■	■	■	■	■	■
Clobetasol (topical)	■	■	■	■	■	■	■	■	■	■	■
Clobetasone (topical)	■	■	■	■	■	■	■	■	■	■	■
Dexamethasone	■	■	■	■	■	■	■	■	■	■	■
Fludrocortisone	■	■	■	■	■	■	■	■	■	■	■
Flunisolide	■	■	■	■	■	■	■	■	■	■	■
Fluticasone	■	■	■	■	■	■	■	■	■	■	■
Hydrocortisone (topical)	■	■	■	■	■	■	■	■	■	■	■
Methylprednisolone	■	■	■	■	■	■	■	■	■	■	■
Mometasone	■	■	■	■	■	■	■	■	■	■	■
Prednicarbate	■	■	■	■	■	■	■	■	■	■	■
Prednisone	■	■	■	■	■	■	■	■	■	■	■
Triamcinolone	■	■	■	■	■	■	■	■	■	■	■

	BOC	DCV	EBR/ GZR	LED/ SOF	OBV/ PTV/r +DSV	OBV/ PTV/r +DSV	SMV	SOF	TVR	VEL/ SOF	RBV
Other Drugs											
Acamprosate	■	■	■	■	■	■	■	■	■	■	■
Acetazolamide	■	■	■	■	■	■	■	■	■	■	■
Acitretin	■	■	■	■	■	■	■	■	■	■	■
Alfuzosin	■	■	■	■	■	■	■	■	■	■	■
Allopurinol	■	■	■	■	■	■	■	■	■	■	■
Atomoxetine	■	■	■	■	■	■	■	■	■	■	■
Atropine	■	■	■	■	■	■	■	■	■	■	■
Baclofen	■	■	■	■	■	■	■	■	■	■	■
Bromocriptine	■	■	■	■	■	■	■	■	■	■	■
Calcitonin	■	■	■	■	■	■	■	■	■	■	■
Calcium resonium	■	■	■	■	■	■	■	■	■	■	■
Carbamazole	■	■	■	■	■	■	■	■	■	■	■
Carisoprodol	■	■	■	■	■	■	■	■	■	■	■
Clostrazol	■	■	■	■	■	■	■	■	■	■	■
Clomifene	■	■	■	■	■	■	■	■	■	■	■
Colchicine	■	■	■	■	■	■	■	■	■	■	■
Colestyramine	■	■	■	■	■	■	■	■	■	■	■
Conivaptan	■	■	■	■	■	■	■	■	■	■	■
Cyclobenzaprine	■	■	■	■	■	■	■	■	■	■	■
Cytisine	■	■	■	■	■	■	■	■	■	■	■
Darbepoetin	■	■	■	■	■	■	■	■	■	■	■
Desmopressin	■	■	■	■	■	■	■	■	■	■	■
Dexamethorphan	■	■	■	■	■	■	■	■	■	■	■
Disulfiram	■	■	■	■	■	■	■	■	■	■	■
Dorzolamide	■	■	■	■	■	■	■	■	■	■	■
Dutasteride	■	■	■	■	■	■	■	■	■	■	■
Epoetin alfa	■	■	■	■	■	■	■	■	■	■	■
Filgrastim	■	■	■	■	■	■	■	■	■	■	■
Finasteride	■	■	■	■	■	■	■	■	■	■	■
Flibanserin	■	■	■	■	■	■	■	■	■	■	■
Gadopentetate (gadolinium)	■	■	■	■	■	■	■	■	■	■	■
Goserelin	■	■	■	■	■	■	■	■	■	■	■
Hyoscine	■	■	■	■	■	■	■	■	■	■	■
Isotretinoin	■	■	■	■	■	■	■	■	■	■	■
Lanreotide	■	■	■	■	■	■	■	■	■	■	■
Levothyroxine	■	■	■	■	■	■	■	■	■	■	■
Melatonin	■	■	■	■	■	■	■	■	■	■	■
Methylphenidate	■	■	■	■	■	■	■	■	■	■	■
Minoxidil	■	■	■	■	■	■	■	■	■	■	■
Modafinil	■	■	■	■	■	■	■	■	■	■	■
Naftidrofuryl	■	■	■	■	■	■	■	■	■	■	■
Naloxone	■	■	■	■	■	■	■	■	■	■	■
Naltrexone	■	■	■	■	■	■	■	■	■	■	■
Neostigmine	■	■	■	■	■	■	■	■	■	■	■
Nicorandil	■	■	■	■	■	■	■	■	■	■	■
Orlistat	■	■	■	■	■	■	■	■	■	■	■
Penicillamine	■	■	■	■	■	■	■	■	■	■	■
Pentoxifylline	■	■	■	■	■	■	■	■	■	■	■
Phenylephrine	■	■	■	■	■	■	■	■	■	■	■
Pilocarpine	■	■	■	■	■	■	■	■	■	■	■
Piracetam	■	■	■	■	■	■	■	■	■	■	■
Potassium	■	■	■	■	■	■	■	■	■	■	■
Protamine sulphate	■	■	■	■	■	■	■	■	■	■	■
Sevelamer	■	■	■	■	■	■	■	■	■	■	■
Strontium ranelate	■	■	■	■	■	■	■	■	■	■	■
Sulfasalazine	■	■	■	■	■	■	■	■	■	■	■
Tamsulosin	■	■	■	■	■	■	■	■	■	■	■
Thalidomide	■	■	■	■	■	■	■	■	■	■	■
Tolterodine	■	■	■	■	■	■	■	■	■	■	■
Tranexamic acid	■	■	■	■	■	■	■	■	■	■	■
Ursodeoxycholic acid	■	■	■	■	■	■	■	■	■	■	■
Varenicline	■	■	■	■	■	■	■	■	■	■	■

For personal use only. Not for distribution.

Key to symbols

■	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
■	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways. Interaction studies performed with boceprevir and telaprevir have shown some inconsistencies which suggest unknown mechanisms may contribute to drug-drug interactions and therefore predictions may not always reflect the clinical situation.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
University of Liverpool,
Pharmacology Research Labs, 1st Floor Block H,
70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or